Pharma Major Lupin’s Canadian subsidiary, Lupin Pharma Canada has launched its first Brand product Zaxine under a strategic licensing agreement with the North Carolina based GI specialty company Salix Pharmaceuticals Inc. The agreement grants Lupin exclusive rights to promote, distribute and market Zaxine in the Canada.
Zaxine, 550 mg, (rifaximin), is a long term antibiotic treatment for adults living with hepatic encephalopathy (HE), a complication of liver disease (cirrhosis). HE can lead to a wide spectrum of mental and physical symptoms, including confusion, disruption in sleep patterns, personality changes and coma Zaxine 550 mg has approved by Health Canada under priority review for the reduction in risk of overt HE recurrence in patients above 18 year of age.
Lupin will advertise and promote the product to hepatologists and gastroenterologists through its own specialty sales force in Canada. It is in the process of establishing its Canadian presence and the launch opens up growth opportunities for the future. Zaxine is a 'First-in-Class' treatment for HE that currently has limited options for long term treatment.
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations as well as biotechnology products and APIs globally. Its products include for applications such as cardiovascular, diabetology, asthma, paediatric, central nervous system (CNS) and anti-infective.
Subscribe to PharmaTutor News Alerts by Email >>
